Mirum Pharmaceuticals Reports Strong Third-Quarter 2026 Results, Raises Full-Year Sales Guidance and Advances Rare Disease Pipeline Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, has reported its financial results for the third quarter…
Ingersoll Rand Announces Key Leadership Appointments to Strengthen Business Operations and Support Next Phase of Growth Ingersoll Rand Inc., a global provider of mission-critical flow creation technologies and life science and industrial solutions, has announced a series of leadership appointments…
Blue Arbor Technologies Raises $10.5 Million in Series A Financing to Advance RESTORE Neuromuscular Interface System Blue Arbor Technologies, Inc., a medical technology company developing advanced neuromuscular interfaces and next-generation prosthetic control solutions for people with limb loss, has closed…
Bayer Plans $2.2 Billion Pharmaceutical Manufacturing Investment in Ohio Bayer has announced plans to invest approximately $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, marking one of the company’s major investments in its U.S. Pharmaceuticals business…
Autobahn Therapeutics Reports Positive Phase 2 AMPLIFY-BD Results for Elunetirom in Bipolar Depression Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people living with neuropsychiatric disorders, announced the presentation of complete results from its Phase 2 AMPLIFY-BD clinical…
Vyome Holdings Appoints Jerry Leonard as Chief Financial Officer to Strengthen Financial Operations and Support Pipeline Development Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biopharmaceutical company developing differentiated therapies for immuno-inflammatory and rare disease conditions, has appointed experienced financial executive…
Gossamer Bio Completes 1-for-80 Reverse Stock Split to Support Nasdaq Listing Compliance Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease…
OnMed CareStation Gains Momentum as States Deploy $50 Billion Rural Health Transformation Funding As states across the United States transition from planning to implementation of approximately $50 billion in federal Rural Health Transformation Program funding, healthcare leaders are increasingly exploring…
Catalent Completes $4.7 Billion Debt Refinancing to Strengthen Financial Position and Support Long-Term Growth Catalent, Inc., a global contract development and manufacturing organization (CDMO) serving the pharmaceutical, biotechnology and healthcare industries, has successfully completed a major debt refinancing transaction designed…
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split to Support Nasdaq Compliance bioAffinity Technologies, Inc., a biotechnology company developing noninvasive technologies for the detection of early-stage cancer, has announced that it will implement a 1-for-15 reverse stock split of its common…
Sinovac Reports 12.9% Revenue Growth in First Half of 2026 as Overseas Vaccine Business Expands Sinovac Biotech Ltd., a leading biopharmaceutical company in China, has announced the filing of its unaudited financial results for the six months ended June 30,…
Zai Lab and argenx Report Positive Phase 3 Results for VYVGART Hytrulo in Autoimmune Myositis Zai Lab Limited and argenx have announced positive topline results from the ALKIVIA Phase 3 clinical study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in…